Dr Lal PathLabs Q1 FY27 Revenue up 19.1% to ₹798 Cr; PAT at ₹170 Cr
Dr Lal PathLabs reported Q1 FY27 consolidated revenue of ₹798 crore, up 19.1%. PAT increased 27.2% to ₹170 crore. The company acquired 80% of Sunshine Healthcare Limited (Ghana) for up to GHS 45.6 million and 30% of Neuome Technologies for up to ₹3.5 crore. An interim dividend of ₹5 per share was declared.
The announcement includes significant financial growth, two strategic acquisitions in the healthcare and technology sectors, and a dividend declaration, all of which are material to the company's performance and shareholder value.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with strategic acquisitions and a dividend payout, indicating positive financial performance and growth initiatives.
Dr. Lal PathLabs Limited announced its un-audited financial results for the quarter ended June 30, 2026, reporting a consolidated revenue of ₹798 crore, an increase of 19.1% compared to the same quarter in the previous fiscal year.
The company's EBITDA for Q1 FY27 grew by 28.7% to ₹247 crore, with a margin of 31.0%. Profit After Tax (PAT) for the quarter stood at ₹170 crore, marking a 27.2% increase and achieving a margin of 21.4%. Earnings Per Share (EPS) was ₹10.1, up 27.8% from ₹7.9 in the prior year's quarter.
In terms of strategic moves, the company has acquired an 80% equity stake in Sunshine Healthcare Limited, Ghana, a diagnostic business, for a consideration not exceeding GHS 45.6 million. Additionally, Dr. Lal PathLabs acquired a 30% equity stake in Neuome Technologies Private Limited, which specializes in innovative solutions for sample preservation and biobanking, for a consideration not exceeding ₹3.5 crore.
The company also declared an interim dividend of 50%, or ₹5 per share. As of June 30, 2026, Dr. Lal PathLabs maintained a healthy liquidity position with cash and cash equivalents amounting to ₹1,693 crore.
What to do with a filing like this
Dr. Lal Path Labs Ltd. filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Lal Path Labs Ltd.. Read the original for the full detail.